Yeast-based vaccines as immunotherapy

Details for Australian Patent Application No. 2003301021 (hide)

Owner Globelmmune, Inc.

Inventors Franzusoff, Alex; Bellgrau, Donald

Agent Freehills

Pub. Number AU-B-2003301021

PCT Number PCT/US2003/0402

PCT Pub. Number WO2004/058157

Priority 60/434,163 16.12.02 US

Filing date 16 December 2003

Wipo publication date 22 July 2004

Acceptance publication date 7 May 2009

International Classifications

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

C12N 15/62 (2006.01) Mutation or genetic engineering - DNA sequences coding for fusion proteins

Event Publications

27 May 2004 Complete Application Filed

  Priority application(s): 60/434,163 16.12.02 US

26 August 2004 Application Open to Public Inspection

  Published as AU-B-2003301021

3 May 2007 Change of Name(s) of Applicant(s), Section 104

  Globeimmune, Inc. The name of the applicant has been changed to Globelmmune, Inc. 2004

7 May 2009 Application Accepted

  Published as AU-B-2003301021

3 September 2009 Standard Patent Sealed

1 October 2009 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 08 Sep 2009. Address for service in Australia - Freehills Patent & Trade Mark Attorneys Level 43 101 Collins Street Mebourne VIC 3000 2004

18 February 2010 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 08 Sep 2009 2004

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003301022-SYSTEM AND METHOD FOR HOME NETWORK CONTENT PROTECTION AND COPY MANAGEMENT

2003301020-ISOQUINOLINONE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS